INSERM, Bordeaux population Health, U1219, I-prev/PHARES, Equipe Labellisée Ligue Contre le Cancer, Université de Bordeaux, Talence, France
ISPED, Chaire Prévention, Université de Bordeaux, Talence, France.
BMJ Open. 2024 Nov 12;14(11):e087541. doi: 10.1136/bmjopen-2024-087541.
In 2021, among French women who smoked when they knew they were pregnant, 59% still smoked at the end of pregnancy. Support for pregnant women to stop smoking must include a structured organisational perspective. The main objective of the study is to evaluate the effectiveness of the 5A-QUIT-N organisational intervention on smoking cessation at delivery among pregnant women who smoke during pregnancy.
The overarching goal of the 5A-QUIT-N intervention, which aims to organise the healthcare professionals monitoring pregnancy, specialists in addiction and tobacco use, and clinical and training tools, using the 5As method. The 5A-QUIT-N intervention will be evaluated in a pragmatic stepped-wedge cluster randomised trial. Within each cluster, during the 6 months before (control) and after (intervention) the intervention, women who smoke tobacco during pregnancy will be enrolled during their maternity stay after delivery. A transition period is planned between the control and intervention periods to deploy the intervention. All participating women will be interviewed using a heteroquestionnaire to assess smoking cessation, tobacco use monitoring by healthcare professionals and individual factors associated with tobacco use during pregnancy. The primary outcome was the point prevalence of abstinence at delivery, which is the proportion of women reporting abstinence from smoking for at least 7 days at delivery. 4200 women who smoked tobacco during pregnancy will be recruited over the entire study period (33 months) to evaluate the effectiveness. An estimated 4585 participants will be included for all aims.
The study will be implemented in accordance with French regulations. The study including the consent process has been independently reviewed and approved by the French ethical board 'CPP Ile de France I' on 10 February 2022 (No CPPIDF1-2022-DI08-cat.2). The results will be disseminated on various academic and non-academic platforms. The results will be reported in international peer-reviewed journals and presented at international and national conferences.
2021 年,在已知怀孕仍吸烟的法国女性中,59%的人在孕期结束时仍在吸烟。支持孕妇戒烟必须包括一个结构化的组织视角。本研究的主要目的是评估在怀孕期间吸烟的孕妇中,5A-QUIT-N 组织干预对分娩时戒烟的效果。
5A-QUIT-N 干预的总体目标是组织妊娠监测的医疗保健专业人员、成瘾和烟草使用专家以及临床和培训工具,使用 5A 方法。5A-QUIT-N 干预将在一个实用的逐步楔形集群随机试验中进行评估。在每个集群中,在干预前(对照)和干预后(干预)的 6 个月内,将在产后产妇住院期间招募怀孕期间吸烟的女性。计划在对照和干预期间之间有一个过渡期来部署干预措施。所有参与的女性将使用异质问卷进行访谈,以评估戒烟情况、医疗保健专业人员对烟草使用的监测以及与怀孕期间烟草使用相关的个人因素。主要结果是分娩时的 abstinence 点患病率,即报告至少 7 天戒烟的女性比例。在整个研究期间(33 个月)将招募 4200 名怀孕期间吸烟的女性,以评估干预的效果。预计将包括 4585 名参与者进行所有目的的研究。
该研究将按照法国法规进行实施。该研究包括同意过程,已由法国伦理委员会“法兰西岛 I 大区 CPP”于 2022 年 2 月 10 日独立审查和批准(CPPIDF1-2022-DI08-cat.2)。研究结果将在各种学术和非学术平台上传播。研究结果将在国际同行评议期刊上发表,并在国际和国内会议上展示。